- Home
- BMEA vs SORA Comparison
BMEA vs SORA Comparison
Compare BMEA & SORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- SORA
- Stock Information
- Founded
- BMEA 2017
- SORA 2001
- Country
- BMEA United States
- SORA Hong Kong
- Employees
- BMEA N/A
- SORA N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- SORA Other Specialty Stores
- Sector
- BMEA Health Care
- SORA Industrials
- Exchange
- BMEA Nasdaq
- SORA Nasdaq
- Market Cap
- BMEA 125.0M
- SORA 111.9M
- IPO Year
- BMEA 2021
- SORA 2025
- Fundamental
- Price
- BMEA $2.15
- SORA $5.08
- Analyst Decision
- BMEA Strong Buy
- SORA
- Analyst Count
- BMEA 8
- SORA 0
- Target Price
- BMEA $10.63
- SORA N/A
- AVG Volume (30 Days)
- BMEA 658.3K
- SORA 32.2K
- Earning Date
- BMEA 10-28-2025
- SORA 01-01-0001
- Dividend Yield
- BMEA N/A
- SORA N/A
- EPS Growth
- BMEA N/A
- SORA N/A
- EPS
- BMEA N/A
- SORA N/A
- Revenue
- BMEA N/A
- SORA $17,619,363.00
- Revenue This Year
- BMEA N/A
- SORA N/A
- Revenue Next Year
- BMEA N/A
- SORA N/A
- P/E Ratio
- BMEA N/A
- SORA N/A
- Revenue Growth
- BMEA N/A
- SORA N/A
- 52 Week Low
- BMEA $1.29
- SORA $3.19
- 52 Week High
- BMEA $13.07
- SORA $14.15
- Technical
- Relative Strength Index (RSI)
- BMEA 61.18
- SORA N/A
- Support Level
- BMEA $1.98
- SORA N/A
- Resistance Level
- BMEA $2.18
- SORA N/A
- Average True Range (ATR)
- BMEA 0.12
- SORA 0.00
- MACD
- BMEA 0.01
- SORA 0.00
- Stochastic Oscillator
- BMEA 75.76
- SORA 0.00
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About SORA Top Win International Limited Ordinary Shares
AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.